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Abstract Although we have recently witnessed sub-
stantial progress in management and outcome of patients
with chronic heart failure, acute heart failure (AHF) man-
agement and outcome have not changed over almost a
generation. Vasodilators are one of the cornerstones of
AHF management; however, to a large extent, none of
those currently used has been examined by large, placebo-
controlled, non-hemodynamic monitored, prospective ran-
domized studies powered to assess the effects on outcomes,
in addition to symptoms. In this article, we will discuss the
role of vasodilators in AHF trying to point out which are
the potentially best indications to their administration and
which are the pitfalls which may be associated with their
use. Unfortunately, most of this discussion is only partially
evidence based due to lack of appropriate clinical trials. In
general, we believe that vasodilators should be adminis-
tered early to AHF patients with normal or high blood
pressure (BP) at presentation. They should not be admin-
istered to patients with low BP since they may cause
hypotension and hypoperfusion of vital organs, leading to
renal and/or myocardial damage which may further worsen
patients’ outcome. It is not clear whether vasodilators have
a role in either patients with borderline BP at presentation
(i.e., low-normal) or beyond the ﬁrst 1–2 days from pre-
sentation. Given the limitations of the currently available
clinical trial data, we cannot recommend any speciﬁc agent
as ﬁrst line therapy, although nitrates in different formu-
lations are still the most widely used in clinical practice.
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Introduction
Hospitalization for AHF remains a major clinical chal-
lenge, with a high and increasing incidence, substantial
morbidity and mortality, and few improvements in therapy
over recent decades. Current pharmacotherapy for AHF
continues to consist primarily of diuretics in almost all the
patients, supplemented by vasodilators or inotropic agents
in selected subsets [1]. However, the use of these agents is
still based on limited evidence, generally from small, single
center studies just focused on their acute hemodynamic
effects. No data regarding outcomes were collected until in
the recent years, and even symptoms were not thoroughly
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ognized in recent guidelines [2, 3], we have very limited
evidence of efﬁcacy for the agents currently used for AHF
treatment (Table 1).
Second,ithasbecomeincreasinglyclearthatAHFisnota
single disease, but rather a heterogeneous family of clinical
syndromes, each with a distinct clinical presentation, prog-
nosis, and management [2, 4–7]. Data from large registries
such as Acutely Decompensated Heart Failure National
Registry (ADHERE) and Organized Program to Initiate
Lifesaving Treatment in Hospitalized Patients with Heart
Failure (OPTIMIZE) have demonstrated that a substantial
portion (over three-fourths) of patients presenting with AHF
have normal or elevated blood pressure (BP) at the time of
presentation. Many guidelines suggest that vasodilator
therapy be considered in AHF patients with high to normal
BP on admission and avoided in those with low BP [2, 3, 8].
The most recent ESC guidelines state that vasodilators ‘‘are
recommended at an early stage for acute heart failure (AHF)
patientswithoutsymptomatichypotension,SBP\90 mmHg
or serious obstructive valvular disease’’ [3].
Despite the high prevalence of AHF with hypertension,
these recommendations are primarily based on expert
opinion rather than large-scale clinical trials. Indeed, none
of the currently approved intravenous vasodilators have
been well studied in the subset of patients in whom they are
recommended, i.e., AHF patients with elevated BP. In this
review, we describe current understanding of the patho-
physiology of AHF with hypertension, the rationale for
vasodilator therapy in these patients, and then review the
available data on approved vasodilators as well as those
under investigation.
Pathophysiology—why should we consider
vasodilators in acute heart failure?
Vasodilators are recommended for the early treatment of
AHF associated with elevated BP at presentation. What is
theunderlyingpathophysiologyinsuchpatients thatsuggest
that vasodilators may be useful? Most studies suggest that
vasoconstriction plays a central role in the pathogenesis of
AHF via multiple mechanisms (Fig. 1). One fundamental
mechanism in AHF is the interaction between a progressive
decrease in cardiac performance and an acute increase in
systemic vascular resistance, the so-called ‘‘afterload mis-
match’’. This leads to a decrease in cardiac output and
increase in left ventricular ﬁlling pressure. The increase in
left ventricular ﬁlling pressure leads to a steep increase in
pulmonary venous and hence pulmonary capillary pressure
inducing exudation of ﬂuid from the intravascular com-
partment into the lung interstitium and alveoli, resulting in
pulmonary congestion and dyspnea.
There are multiple further mechanisms which may con-
tribute to symptoms and the poor prognosis of patients with
AHF, and they have been recently reviewed in detail [7, 9,
10].First,ascongestionincreases,O2saturationdeteriorates
and systemic O2 desaturation contributes to insufﬁcient
myocardialO2supplyandpossiblymyocardialischemiaand
damage. This mechanism may be further favored by con-
comitantcoronaryarterydisease,coronaryvasoconstriction,
caused by neurohormonal activation, and by increased
myocardial oxygen demand from increased wall stress sec-
ondary to the afterload mismatch. Second, the increased
ﬂuid content in the lungs and decreased O2 saturation may
inducepulmonaryvasoconstrictionwithafurtherincreasein
RV pressure, again compromising left ventricular function
through the ventricular interaction mechanism. Third, pro-
foundcirculatoryinsufﬁciencyresultsinmetabolicacidosis,
which further jeopardizes cardiac performance. Fourth,
inﬂammatory and neurohormonal activation can lead to
multiple consequences affecting cardiac and renal function
as well as pulmonary membranes leading to increased
‘‘leak’’ of ﬂuid into alveoli, further amplifying congestion.
Finally, decreased forward perfusion, increased venous
pressure, and neurohormonal-inﬂammatory activation lead
to further impairment in renal function that in turn worsens
heart failure.
As noted above, large registries such as ADHERE and
OPTIMIZE demonstrate that most patients with AHF have
either preserved or increased BP at presentation [5, 11].
These registries may actually underestimate the importance
Table 1 Medical treatment for
acute heart failure in recent
European Society of Cardiology
guidelines [2, 3]
In the most recent ESC
guidelines [3] both nitrates and
sodium nitroprusside are
considered together and have a
level of evidence B (*) and
milrinone and enoximone have
a level of evidence B (**)
Group Medication Class of recommendation Level of evidence
Diuretics Mainly loop diuretics I B
Vasodilators Nitrates I B
Sodium nitroprusside I C*
Morphine Morphine IIb B
Inotropes Dopamine IIb C
Dobutamine IIa C
Milrinone, enoximone IIb C**
Levosimendan IIa B
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123of hypertension, because the ﬁrst BP recorded was usually
a few hours after presentation and sometimes after initial
treatment was administered. In a recent comprehensive
small study that captured the initial BP in the emergency
department or in the ambulance in all the patients admitted
with AHF to a community hospital, the vast majority of
patients were hypertensive at admission with only about
10% of patients having ‘‘normal’’ or low BP at presentation
[12]. In a hemodynamic study where data were collected in
patients admitted to the hospital with an AHF event, the
most notable change in hemodynamic measures leading to
heart failure was a very steep increase in vascular resis-
tance and BP [13]. Patients admitted for AHF with high BP
are more likely to be females, elderly, with a history of
hypertension, and with a normal left ventricular ejection
fraction [14, 15].
Taken as a whole, these data suggest that changes in
vascular tone, possibly both on the arterial side (increasing
afterload) and venous side (increasing pre-load), are
important contributors to AHF and may be a crucial
determinant of the AHF syndrome in patients with AHF
and elevated BP (recently termed acute vascular or car-
diovascular AHF).
Potential risks and beneﬁts of vasodilators in AHF
Treatment goals in AHF should be aligned with the general
principles of drug therapy—i.e., that interventions in
any disease should make patients ‘‘feel better’’ and/or ‘‘live
longer’’. Vasodilators in AHF were traditionally developed
to make patients ‘‘feel better’’, which in AHF has typically
been assessed as the early and sustained relief of dyspnea.
As with all symptoms relief, however, it is crucial that
such improvement is not achieved at the expense of
greater ‘‘downstream’’ risks for outcomes such as end-
organ damage, hospitalization, or death. Avoidance of
hypotension and end-organ hypoperfusion seems to play a
crucial role.
Despite their long history of use, the body of evidence to
understand the safety proﬁle of vasodilators in AHF
remains limited. Retrospective analyses of pooled data for
nesiritide suggested the possibility of worsening renal
function and increased mortality, leading to substantial
controversy about the safety of this agent [16, 17]. Of note,
in the studies that were used for this meta-analysis, patients
with systolic BPs \90 mmHg were allowed. In patients
with low systolic BP, renal perfusion might be seriously
jeopardized when a vasodilator is added, leading to
increased risks of worsening renal function. In other groups
of patients with systolic dysfunction, nesiritide treatment
was not associated with worsening renal function nor was
even related to improvement of renal dysfunction [18, 19].
Further concerns are related to the effects of vasodilators
on coronary perfusion and myocardial damage. Studies
based on serial measurements of serum troponin levels
have shown that a consistent proportion of AHF patients,
also including patients with idiopathic dilated cardiomy-
opathy, develop myocardial damage at the time of their
admission. In a study by Metra et al., detectable serum
Fig. 1 The central role of
vasoconstriction in the
pathogenesis of acute heart
failure. (modiﬁed from:
Teerlink JR, O’Connor CM.
Endothelin receptor antagonists
in the treatment of acute heart
failure. In CM O’Connor, WG
Stough, M Gheorghiade, KF
Adams (editors): Managing
Acute Decompensated Heart
Failure: A Clinician’s Guide for
Diagnosis and Treatment.
London, Taylor and Francis,
LTD, 2005)
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123troponin T levels were found in 48% of the patients
admitted for AHF (54% of the patients with coronary artery
disease and 40% of those with idiopathic dilated cardio-
myopathy) [20]. Excessive hypotension may lead to
coronary hypoperfusion and cause myocardial damage.
Further, although this is not the case for nitrates, vasodi-
lators may preferentially dilate normal coronary vessels
causing ‘‘coronary steal’’ with further decline of blood ﬂow
in diseased vessels.
The results of one of the earliest randomized, placebo-
controlled, double-blind trials of vasodilators in patients
with left ventricular dysfunction were actually consistent
with the hypothesis that vasodilators may be detrimental in
patients with ongoing myocardial ischemia. In this trial,
Cohn et al. randomized 812 men with presumed acute
myocardial infarction and left ventricular ﬁlling pressure
C12 mmHg to a placebo or sodium nitroprusside 48 h
infusion. Results on mortality were strongly affected by the
time of treatment with a deleterious effect of sodium
nitroprusside when infusion was started at \9 h from the
onset of symptoms (mortality at 13 weeks, 24.2% vs.
12.7%; P = 0.025) and a beneﬁcial effect in those whose
infusion was begun later (mortality at 13 weeks, 14.4% vs.
22.3%; P = 0.04) [21]. These results are consistent with
the hypothesis that vasodilator therapy may aggravate
coronary hypoperfusion and, when associated with hypo-
tension, may be deleterious in the setting of myocardial
ischemia. They, however, also show that vasodilator
treatment may favorably affect outcomes when used
appropriately in patients with cardiac dysfunction.
More recent data also indicate that excessive peripheral
vasodilatation may be deleterious in patients with AHF. A
retrospective analysis of data from the Evaluation Study of
Congestive Heart Failure and Pulmonary Artery Catheter-
ization Effectiveness (ESCAPE) has shown that the
combination of intravenous vasodilators and inotropes is
associated with a risk-adjusted increased mortality which is
even higher (hazard ratio, HR, 4.81, 95% conﬁdence
intervals, CI, 2.34–9.90) than with inotropes alone (HR,
2.14, 95% CI 1.10–4.15). Vasodilators alone, however,
were not associated with a signiﬁcant increase in the risk of
death (HR, 1.39, 95% CI 0.64–3.00). Similar data were
found when the combined end-point of death plus rehos-
pitalizations were considered [22]. Consistently, the lack of
improvement in outcomes with levosimendan, compared to
dobutamine, in SURVIVE has been ascribed also to the
vasodilatatory effects and hypotension associated with
levosimendan administration as observed in this trial [23].
Thus, we are left with doubts regarding the effects of
vasodilators on outcomes, and even symptoms, in the
patients with AHF. No single study of vasodilators in AHF
has been sufﬁciently powered to carefully evaluate safety,
andinparticular,noadequatelypoweredprospectivestudies
have been performed with nitrates or sodium nitroprusside,
the most commonly used vasodilators in AHF. Do vasodi-
lators as a class lead to worsening renal function, end-organ
damage, or increase the rate of post-discharge re-admission
and death in AHF? Although currently available data do not
permit a deﬁnitive answer to this question, we believe that
the answer is no. First, we believe that safety of vasodilator
therapy can be signiﬁcantly increased by focusing on those
patients most likely to beneﬁt: patients with AHF and nor-
mal or elevated BP. In addition, careful monitoring of BP
during treatment and down titration or discontinuation of
vasodilator therapy, if BP drops signiﬁcantly, may improve
the safety proﬁle of these agents. Finally, these agents may
have U-shaped dose–effect relationships. While it is widely
recognized that sub-optimal doses of vasodilators may have
a limited effect, administration of high doses might also
reduce their effectiveness because of counter regulatory
mechanisms. In some cases, vasodilators doses were chosen
based on small hemodynamic studies largely conﬁned to
patients with stable severe chronicheartfailure with systolic
dysfunction. The doses chosen were those achieving the
maximal possible vasodilatation, or largest increase in car-
diac index and decrease in pulmonary wedge pressure
(PWP). However, in patients with AHF in whom cardiac
reserve is reduced, inappropriate vasodilatation may induce
a steep reduction in BP, resulting in hemodynamic insta-
bility,ischemia,renalfailure,andsometimesfrankshock.In
addition, high-dose vasodilators can induce rebound neu-
rohormonal activation potentially limiting short- and long-
termefﬁcacy[24–26].Therefore,theadministrationofthese
drugs shouldbedonewithcaution,tothepatientswhoreally
deserve them, using the right doses, under careful BP
monitoring, and with careful titration of the dose according
to changes in BP. Large, carefully controlled prospective
studies will be required to provide conclusive evidence of
the safety and efﬁcacy of vasodilator therapy in AHF.
Choice of vasodilator in AHF: currently available
therapies
Nitrovasodilators
Nitrates, which have been used as vasodilators in AHF for
many years, have never been evaluated in a prospective
randomized study. In small studies, nitrates have been
shown to improve some aspects of the AHF syndrome. In
the VMAC study, ﬁxed low doses of nitrates were shown to
improve some aspects of dyspnea during the ﬁrst hours of
administration [27]. However, no prospective randomized
study has examined the use of higher doses, above all with
the option of careful dose titration according to BP chan-
ges, on any component of the clinical syndrome of AHF.
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123Cotter et al. have shown that high-dose early administra-
tion of intravenous nitrates is beneﬁcial in improving
arterial oxygenation or potentially preventing some con-
sequences of AHF (myocardial infarction [MI], need for
mechanical ventilation), compared to furosemide alone
[28] or noninvasive ventilation [29], respectively, although
these studies were small and not blinded. The effects of
nitrates on end-organ damage (renal impairment, MI, car-
diac arrest) or on intermediate and long term outcomes (re-
admission and death) were never examined. Importantly,
the use of continuous intravenous administration of nitrates
beyond a few hours is associated with tolerance, and to
maintain efﬁcacy, nitrates need to be continuously up-
titrated against BP [30].
Sodium nitroprusside is an intravenous vasodilator
commonly used in the past in patients with refractory heart
failure. It is administered almost exclusively in critical care
settings, sometimes with careful invasive hemodynamic
monitoring to avoid the risk of inducing hypotension.
Accurate non-invasive BP monitoring is also a reasonable
alternative to invasive measurements. Prolonged use of
nitroprusside has been rarely associated with the risk of
thiocyanate toxicity. Neurohormonal activation and
rebound vasoconstriction after its abrupt withdrawal have
been described [24, 31]. These concerns have hindered the
general enthusiasm in using nitroprusside in the contem-
porary management of AHF, even though its favorable
hemodynamic effects have been well documented. A recent
analysis by Mullens et al. of 175 consecutive patients
admitted for acutely decompensated heart failure, showed
that intravenous sodium nitroprusside, although adminis-
tered to the patients with a worse hemodynamic proﬁle at
baseline, was associated with greater hemodynamic
improvement and lower rates of inotropic support or
worsening renal function during hospitalization and with
lower rates of all-cause mortality after discharge [32].
Nesiritide
Nesiritide is the only vasodilator recently approved for the
treatment of AHF. Approval, however, accorded by the US
Food and Drug Administration and not by European regu-
latory agencies [2, 3, 8]. Early studies demonstrated
favorable effects on hemodynamics, including reductions in
PWP and systemic vascular resistance which were accom-
panied by an increase in cardiac output [33, 34]. These
results were conﬁrmed by the Vasodilatation in the Man-
agement of Acute Congestive Heart Failure (VMAC) study
that showed some beneﬁcial effects of nesiritide on dyspnea
in patients admitted for AHF, half of whom were monitored
by pulmonary artery catheters. Dyspnea improvement was
demonstrated at 3 h compared to the placebo group [27].
However, besides this short-term improvement in dyspnea,
other effects of nesiritide, such as persistence of the dyspnea
improvement, potential harmful effects on end organs or
increased re-admission and death, have not been studied
prospectively in a large number of patients. Moreover,
additional data analysis raised concerns regarding its safety,
with respect to its effects on kidney function and short-term
mortality [16, 17]. Currently, the on-going Acute Study of
Clinical Effectiveness of Nesiritide in Subjects with
Decompensated Heart Failure (ASCEND-HF) study is
addressing these issues in 7,000 patients admitted with AHF
and randomized to nesiritide or placebo.
Choice of vasodilator in AHF: investigational
therapies
Endothelin antagonists
Endothelin (ET)-1 is a powerful vasoconstrictor that is
used increasingly in heart failure and when higher ET-1
levels are observed in patients with more symptomatic
heart failure [35–37]. Furthermore, ET-1 was shown to
correlate with the outcome of patients admitted for
decompensated AHF [38]. On the basis of these patho-
physiological data, several endothelin antagonists were
developed for potential cardiovascular use, including da-
rusentan, sitaxsentan, bosentan, and tezosentan.
Tezosentan is an intravenous dual (ETA and ETB)
receptor-competitive antagonist of endothelin-1 (ET-1) that
was extensively studied in AHF. It is associated with va-
sodilatory effects that result in increased cardiac index and
reduced PWP. The hemodynamic and clinical effects of
tezosentan were evaluated in a series of large double-blind,
parallel-group, phase III studies, collectively known as the
RITZ (Randomized Intervention of TeZosentan) program.
Even though safety trials showed that tezosentan was rel-
atively safe in high-risk patients with AHFS associated
with acute coronary syndromes or with acute cardiogenic
pulmonary edema, the results of the RITZ program did not
demonstrate a clinical beneﬁt as there was no reduction in
the rate of recurrent heart failure events in the tezosentan-
treated patients despite signiﬁcant hemodynamic effects
[39–42]. The Value of Endothelin Receptor Inhibition with
Tezosentan in Acute Heart Failure Study (VERITAS) [43,
44] was a large-scale international trial designed to study
the effects of tezosentan added to conventional therapy in
patients with AHF hospitalized for dyspnea, on dyspnea
relief and worsening HF events. The trial was discontinued
because of the low probability of achieving a signiﬁcant
treatment effect, after a recommendation based on pre-
speciﬁed rules by the Data Safety and Monitoring Board.
Hence, there is no clear evidence to support administration
of endothelin antagonists in AHF.
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Ularitide
Ularitide is a synthetic analogue of urodilatin, a member of
the family of atrial or A-type natriuretic peptides (ANP)
produced locally in the renal tubular cells which plays an
important role in sodium and water excretion [45]. Early
studies in patients with HF reported favorable hemody-
namic effects and possibly enhanced diuresis and
natriuresis with ularitide. SIRIUS I (24 patients) [46] and
SIRIUS II (221 patients) [47, 48] studied three doses of
ularitide compared to placebo among patient hospitalized
with AHF. Ularitide was found to have beneﬁcial symp-
tomatic, hemodynamic (PWP and cardiac index), and
neurohormonal effects. The most frequent adverse event
was hypotension, reported in up to 5% in active groups.
Ularitide has not been studied in a large prospective ran-
domized study examining either symptoms improvement
or outcome of patients with AHF.
CD-NP
CD-NP is a chimeric natriuretic peptide—a fusion peptide
of the full-length 22-AA structure of c-type natriuretic
peptide (CNP) together with the 15-AA C-terminus of
d-type natriuretic peptide (DNP). In animal models, CD-NP
was shown to have natriuretic and diuretic, glomerular
ﬁltration rate (GFR)-enhancing, renin inhibiting and
unloading effects, with less hypotensive properties when
compared to BNP. In addition, CD-NP in vitro possesses
cGMP activating and anti-proliferative properties in cul-
tured ﬁbroblasts. Preliminary data suggest that the drug is a
more selective venovasodilator and diuretic/natriuretic
agent. This drug is being evaluated in phase II human
studies in patients with heart failure and AHF [49].
Relaxin
Relaxinisapeptidemadeupof53aminoacidswhich shares
structural (although not functional) similarities with insulin
includingitsproductionasasingle-chainmoleculethatfolds
and undergoes removal of a C-peptide to yield a 2-chain
molecule with conserved disulﬁde bonds. Relaxin’s activity
is initiated by binding to its cognate receptor, LGR7, which
is present in the renal and systemic vasculature [50].
Importantly, relaxin has multiple mechanisms of action
including effects on nitric oxide (NO) [51], the endothelin
type B receptor [52], atrial natriuretic peptide [53], and
vascular endothelial growth factor in the endometrium [54].
Relaxin also activates matrix metalloproteinases (MMPs)
that may lead to increase in arterial compliance. In a
single site, open-label study of relaxin in patients with
compensatedheartfailureintravenousrelaxingivenfor24 h
was associated with decreases from baseline in PWP and
systemic vascular resistance, and increases in cardiac index,
all of which achieved statistical signiﬁcance at certain time
points, although the PWP decreases were observed at lower
doses than the increases in cardiac output. No consistent
changes in heart rate or BP were observed either during or
post-dosing. The early administration of relaxin is currently
being tested in a phase II/III program (RELAX-AHF) in
patients with AHF and high BP at the time of admission.
BAY 58-2667—NO and heme-independent soluble G
protein activator
A major pathway of vascular tone control is mediated by
NO. Binding of NO to the ferrous heme iron of soluble
guanylate cyclase (sGC) activates the enzyme and leads to
conversion of GTP to cGMP, which leads to vasodilatation.
BAY 58-2667 activates sGC not only independently of NO
but also independently of the prosthetic heme group. In a
model of tachycardia pacing-induced severe heart failure,
BAY 58-2667 caused a dose–dependent reduction in BP,
right atrial, pulmonary artery pressure, and PWP an
increase in cardiac output and renal blood ﬂow, with no
change in glomerular ﬁltration rate, urine ﬂow and urine
sodium excretion [55]. Similar effects were observed in a
small proof of concept study in patients with acute
decompensated heart failure [56]. Phase II and III studies
with this compound in AHF are planned. Theoretically,
BAY 58-2667 may induce predictable and easily reversible
effects on vascular tone that are endothelium independent,
and hence reproducible, even in patients with severe
endothelial dysfunction.
Adenosine blockers—selective renal vasodilatation
Administration of loop diuretics to patients with AHF is
attended by a decrease in renal blood ﬂow and glomerular
ﬁltration rate. This response (the so-called tubuloglomer-
ular mechanism) is mediated by adenosine release caused
by the activation of the juxtaglomerular apparatus cells
which sense the furosemide-associated increased sodium
loading at the level of the distal tubule. Adenosine release
causes a decrease in renal blood ﬂow and GFR through
constriction of the afferent glomerular arteriole mediated
by type-1A adenosine receptors. Early studies have shown
that the co-administration of adenosine type-1A receptor
antagonists may blunt the decrease in GFR associated with
furosemide administration in patients with heart failure
[57]. Seminal work by Dittrich et al. showed that the
administration of the selective adenosine A1 blocker, rol-
ofylline signiﬁcantly increases both renal blood ﬂow and
glomerular ﬁltration rate in patients with heart failure [58].
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showed that the administration of type 1A adenosine
antagonists increases diuresis and natriuresis with a con-
comitant preservation of renal function in patients with
acutely decompensated heart failure and ﬂuid overload
[59]. In the PROTECT pilot study Cotter & Dittrich et al.
have shown that the administration of the A1 receptor
antagonist, rolofylline, to patients with AHF may induce
improvement in dyspnea and have reno-protective effects
that translated into trends in reduced rates of re-admission
and death up to 2 months from treatment [60]. These
potential beneﬁcial effects are examined in a series of
phase II and III studies in which the safety and efﬁcacy of
the above mentioned drugs are examined in detail.
Conclusions
Vasodilators may be beneﬁcial in patients with AHF.
However, this has never been shown in a prospective well-
powered and conducted study. Some newer and older drugs
are being tested and the results of these studies should
enable us to ﬁnally answer some important clinical ques-
tions, including the following:
(a) Do vasodilators make patients ‘‘feel better’’?
(b) Is this effect clinically signiﬁcant (i.e., appears early,
is sustained, and potentially leads to shorter length of
hospital stay)?
(c) Can these effects be achieved without collateral
damage to vital organs such as the kidney, heart
and brain—or even while improving these organ
functions?
(d) Can this be achieved without leading to detrimental
effects on re-admission or death or even reduce these
outcomes?
(e) Which patients should be treated and for how long?
(f) Are all vasodilators equal or are veno vasodilators or
renal vasodilators superior?
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